Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

931 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y. Mabuchi S, et al. Among authors: sakata m. Clin Cancer Res. 2004 Nov 15;10(22):7645-54. doi: 10.1158/1078-0432.CCR-04-0958. Clin Cancer Res. 2004. PMID: 15569997
Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo.
Hashimoto K, Morishige K, Sawada K, Ogata S, Tahara M, Shimizu S, Sakata M, Tasaka K, Kimura T. Hashimoto K, et al. Among authors: sakata m. Biochem Biophys Res Commun. 2007 Apr 27;356(1):72-7. doi: 10.1016/j.bbrc.2007.02.102. Epub 2007 Feb 28. Biochem Biophys Res Commun. 2007. PMID: 17343825
In our previous study, GGA was shown to inhibit ovarian cancer invasion by attenuating Rho activation [K. Hashimoto, K. Morishige, K. Sawada, M. Tahara, S. Shimizu, M. Sakata, K. Tasaka, Y. Murata, Geranylgeranylacetone inhibits lysophosphatidic acid-induced …
In our previous study, GGA was shown to inhibit ovarian cancer invasion by attenuating Rho activation [K. Hashimoto, K. Morishige, K. Sawada …
931 results